The Valley Desk

Clinical trial reportESMO openPublished

Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
ESMO open
Published
Subject terms
Humans; Pyrazoles; Quinoxalines; Cohort Studies; Aged; Middle Aged; Female; Male; Receptor, Fibroblast Growth Factor, Type 3; Clinical Trial; Advanced Urothelial Carcinoma; Fgfr Inhibitor
PubMed ID
42815410
PubMed Central ID
PMC13654028
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal